Project Details
| Status | Finished |
|---|---|
| Effective start/end date | 12/18/17 → 12/18/20 |
Funding
- Chiltern International, Inc. (MSDC-0602K-C009NASH // MSDC-0602K-C009NASH)
- Cirius Therapeutics, Inc. (MSDC-0602K-C009NASH // MSDC-0602K-C009NASH)
Protocol No. MSDC-0602K-C009NASH: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 12-Month, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC 0602K in Patients with NASH (EMMINENCE™)
- Rinella, Mary Eugenia (PD/PI)
Project: Research project